University Health Network, Toronto: Leukemia trials
The registry lists 25 Leukemia studies with University Health Network, Toronto as lead sponsor. 3 are open to participants now and 3 have results posted.
Phase 1 9Phase 2 10Phase 4 1No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)RecruitingNCT05403177
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT03702309
- Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
- An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01532700Phase 2Results posted
- Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction ChemotherapyCompletedNCT01334086Phase 2Results posted
- Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00751296Phase 2Results posted
- Peer Support Group for Adolescent and Young Adult (AYA) Allogeneic Stem Cell Transplant RecipientsCompletedNCT06704243Not applicable
- Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot StudyCompletedNCT05236296Not applicable
- Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid LeukemiaCompletedNCT03027102Phase 1
- Emotion And Symptom-focused Engagement (EASE): An Intervention for Individuals With Acute LeukemiaCompletedNCT02353559Not applicable
- Allogeneic SCT for CML, TKI Failure After TKI FailureStatus unknownNCT02172365
- Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
- An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction ChemotherapyCompletedNCT01446081Phase 2
- Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid LeukemiaCompletedNCT01332786Phase 1
- Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaTerminatedNCT01222143Phase 1/2
- Quality of Life Study for Adult Patients With Acute Lymphoblastic LeukemiaCompletedNCT01148927
- Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALLTerminatedNCT01148134
- Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic LeukemiaCompletedNCT01133743Phase 2
- A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid LeukemiaCompletedNCT01126814Phase 1/2
- Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
- Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
- Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsCompletedNCT00957385Phase 2
- Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on ImatinibTerminatedNCT00461929Phase 4
- Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00101153Phase 1
- Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedNCT00045513Phase 1/2